Cargando…

Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival

Multiple myeloma (MM) is a cancer of bone marrow (BM) plasma cells, which is increasingly treatable but still incurable. In 90% of MM patients, severe osteolysis results from pathological interactions between MM cells and the bone microenvironment. Delineating specific molecules and pathways for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hathi, Deep, Chanswangphuwana, Chantiya, Cho, Nicholas, Fontana, Francesca, Maji, Dolonchampa, Ritchey, Julie, O’Neal, Julie, Ghai, Anchal, Duncan, Kathleen, Akers, Walter J., Fiala, Mark, Vij, Ravi, DiPersio, John F., Rettig, Michael, Shokeen, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741970/ https://www.ncbi.nlm.nih.gov/pubmed/34996933 http://dx.doi.org/10.1038/s41598-021-03748-0

Ejemplares similares

In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [(18)F]FDG and [(64)Cu]Cu-LLP2A PET
por: Ghai, Anchal, et al.
Publicado: (2021)

First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging
por: Laforest, Richard, et al.
Publicado: (2023)

Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer
por: Kotagiri, Nalinikanth, et al.
Publicado: (2018)

Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2022)

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
por: O’Neal, Julie, et al.
Publicado: (2022)

Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
por: Nair-Gupta, Priyanka, et al.
Publicado: (2020)

Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria
por: Pengpis, Nawaporn, et al.
Publicado: (2023)

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
por: Kim, Miriam Y., et al.
Publicado: (2022)

Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
por: Alahmari, Bader, et al.
Publicado: (2018)

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2021)

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation
por: Asawapanumas, Thiti, et al.
Publicado: (2022)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Mobilized peripheral blood: an updated perspective
por: Karpova, Darja, et al.
Publicado: (2019)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide
por: Crees, Zachary D., et al.
Publicado: (2023)

Prognostic factors and impact of CMV reactivation on acute myeloid leukemia patients after HLA-matched myeloablative allogeneic stem cell transplantation in a high CMV prevalence country
por: Chanswangphuwana, Chantiya, et al.
Publicado: (2023)

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5
por: White, Brian S., et al.
Publicado: (2018)

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
por: Kim, Miriam Y., et al.
Publicado: (2021)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
por: Goldsmith, Scott R, et al.
Publicado: (2023)

Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture
Publicado: (1992)

P1189: ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY
por: Thanhakun, Ronakrit, et al.
Publicado: (2023)

Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease
por: Choi, Jaebok, et al.
Publicado: (2018)

Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins
Publicado: (1995)

Cell adhesion and migration are regulated at distinct stages of thymic T cell development: the roles of fibronectin, VLA4, and VLA5
Publicado: (1996)

CC16 drives VLA-2-dependent SPLUNC1 expression
por: Iannuzo, Natalie, et al.
Publicado: (2023)

ROSAT/ASCA/VLA studies of solar proxies
por: Güdel, M, et al.
Publicado: (1996)

Suicide genes: monitoring cells in patients with a safety switch
por: Eissenberg, Linda G., et al.
Publicado: (2014)

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)

Cold agglutinin disease following SARS‐CoV‐2 and Mycoplasma pneumoniae co‐infections
por: Moonla, Chatphatai, et al.
Publicado: (2020)

Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis
Publicado: (1991)

CNS accumulation of regulatory B cells is VLA-4-dependent
por: Lehmann-Horn, Klaus, et al.
Publicado: (2016)

Integrin-directed antibody-based immunotherapy: focus on VLA-4
por: Savino, Wilson, et al.
Publicado: (2021)

Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
por: Yao, Lijun, et al.
Publicado: (2023)

Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
por: Xiang, Jingyu, et al.
Publicado: (2022)

Regulation of the VLA integrin-ligand interactions through the beta 1 subunit
Publicado: (1992)

The L1 adhesion molecule is a cellular ligand for VLA-5
Publicado: (1995)

The integrin VLA-4 supports tethering and rolling in flow on VCAM-1
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_blpeorlao654dcmvjj0bqajfb1